ALXO NASDAQ
ALX Oncology Holdings Inc.
1W: -6.9%
1M: -41.4%
3M: -44.3%
YTD: +6.1%
1Y: -32.6%
3Y: -74.4%
5Y: -98.4%
$1.22
-0.08 (-6.15%)
Weekly Expected Move ±9.0%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (48)
ALX Oncology (NASDAQ:ALXO) Stock Price Up 3% – Here’s What Happened
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
7,399,530 Shares in ALX Oncology Holdings Inc. $ALXO Acquired by BlackRock Inc.
5AM Venture Management LLC Makes New Investment in ALX Oncology Holdings Inc. $ALXO
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
ALX Oncology GAAP EPS of -$0.17 beats by $0.02
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Recommendation of “Moderate Buy” by Analysts
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
IBRX Stock Jumps on Progress in NK Cell Therapy Production
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study
RLMD Stock Surges 42% in a Week: Here's What You Should Know
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma
EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
QURE Stock Crashes 32% in a Week: Here's What You Should Know
Mirum Completes Enrollment & Screening in Liver Disease Studies
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
ALX Oncology (ALXO) Q4 2025 Earnings Transcript
ALX Oncology GAAP EPS of -$0.42 misses by $0.06
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Corey Goodman Acquires 3,184,713 Shares of ALX Oncology (NASDAQ:ALXO) Stock
ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0%
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting